Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT ID: NCT04551677

Last Updated: 2025-09-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 90 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-09-16
• Study Completion Date: 2020-12-18

Brief Summary

Primary Objective:

To provide serum samples (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to Center for Biologics Evaluation and Research (CBER) for further analysis by the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA) to support formulation recommendations for subsequent influenza vaccines. In addition, serum samples from adult participants may be further analyzed by the Sponsor to assess breadth of immune response induced by the study vaccines.

Detailed Description

Study duration per participant was approximately 28 days for participants 6 months to less than (<) 9 years of age, and 21 days for participants greater than or equal to (>=) 65 years of age, including 1 to 3 visits (1 or 2 vaccination visits) and 1 or 2 telephone calls, depending on study Group.

The aim of study GRC00101 was to obtain serum samples for submission to CBER to aid in the influenza vaccine strain selection process. There were no outcome measures defined in the protocol; however, the number of collected samples was listed as an outcome for disclosure purposes since outcomes were mandatory for study registration.

Conditions

Influenza Immunization; Healthy Volunteers

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Group 1: Fluzone Quadrivalent Influenza Vaccine: 6 to <36 Months

Participants aged 6 to \<36 months received a 0.5-milliliters (mL) dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per Advisory Committee on Immunization Practices (ACIP), a second dose was administered at Day 28.

Group Type: EXPERIMENTAL

Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation

Intervention Type: BIOLOGICAL

Pharmaceutical form: Suspension for injection in a pre-filled syringe,

Route of administration: Intramuscular (IM)

Group 2: Fluzone Quadrivalent Influenza Vaccine: 3 to <9 Years

Participants aged 3 to \<9 years received a 0.5-mL dose of Fluzone Quadrivalent vaccine, intramuscularly, at Day 1. Participants for whom 2 doses of influenza vaccine were recommended per ACIP, a second dose was administered at Day 28.

Group Type: EXPERIMENTAL

Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation

Intervention Type: BIOLOGICAL

Pharmaceutical form: Suspension for injection in a pre-filled syringe,

Route of administration: Intramuscular (IM)

Group 3: Fluzone High-Dose Quadrivalent Influenza Vaccine: >=65 Years

Participants aged \>=65 years received a 0.7-mL dose of Fluzone High-Dose Quadrivalent vaccine intramuscularly at Day 1.

Group Type: EXPERIMENTAL

Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation

Intervention Type: BIOLOGICAL

Pharmaceutical form: Suspension for injection in a pre-filled syringe,

Route of administration: IM

Interventions

Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation

Pharmaceutical form: Suspension for injection in a pre-filled syringe,

Route of administration: Intramuscular (IM)

Intervention Type: BIOLOGICAL

Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation

Pharmaceutical form: Suspension for injection in a pre-filled syringe,

Route of administration: IM

Intervention Type: BIOLOGICAL

Other Intervention Names

Fluzone® Quadrivalent; Fluzone High-Dose Quadrivalent

Eligibility Criteria

Inclusion Criteria

• Aged 6 months to <9 years or >=65 years of age on the day of first study vaccination (study product administration).
• For participants 6 to <12 months of age, born at full term of pregnancy (>=37 weeks) and with a birth weight >=5.5 pound (lbs) (2.5 kilograms [kg]).
• Informed consent form (ICF) was signed and dated by participants >=65 years of age.
• Assent form was signed and dated by participants 7 to <9 years of age, and ICF was signed and dated by parent(s) or guardian(s) for participants 6 months to < 9years of age.
• Participants and parent/guardian (of participants 6 months to <9 years of age) were able to attend all scheduled visits and to comply with all study procedures.

Exclusion Criteria

• Participation at the time of study enrollment (or in the 30 days preceding the first study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure.

Note: Participants were considered eligible for enrollment if no intervention for the other study occurred within the 30 days prior to the first study vaccination and none are planned before the participant would complete safety surveillance for the present study.

• Receipt of any vaccine in the 30 days preceding the first study vaccination, or planned receipt of any vaccine before Visit 2 for participants received 1 dose of influenza vaccine or Visit 3 for participants received 2 doses of influenza vaccine.
• Previous vaccination against influenza (in the 2020-2021 influenza season) with either study vaccine or another vaccine.
• Receipt of immune globulins, blood, or blood-derived products in the 3 months preceding planned inclusion.
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the 6 months preceding planned inclusion; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the 3 months preceding planned inclusion).
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to study vaccine or to a vaccine containing any of the same substances.

Note: The list of vaccine components was included in the Prescribing Information for each study vaccine.

• Thrombocytopenia, which might be a contraindication for IM vaccination, at the discretion of the Investigator.
• Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
• Current alcohol abuse or drug addiction.
• Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with study conduct or completion.
• Moderate or severe acute illness/infection (according to Investigator judgment) on the day of planned vaccination or febrile illness (temperature >=100.4 degree [°] Fahrenheit [38.0° Celsius]). A prospective participant not included in the study until the condition had resolved or the febrile event had subsided.
• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) or in-laws of the Investigator or employee with direct involvement in the proposed study.
• History of serious adverse reaction to any influenza vaccine.
• Personal history of Guillain-Barré syndrome.
• Any condition that in the opinion of the Investigator would pose a health risk to the participant if enrolled or could interfere with the evaluation of the vaccine.
• Personal history of clinically significant developmental delay (at the discretion of the Investigator), neurologic disorder, or seizure disorder.
• Known seropositivity for human immunodeficiency virus, hepatitis B, or hepatitis C.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

• Minimum Eligible Age: 6 Months
• Maximum Eligible Age: 84 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Sanofi Pasteur, a Sanofi Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Clinical Sciences & Operations

Role: STUDY_DIRECTOR

Sanofi Pasteur, a Sanofi Company

Locations

Investigational Site Number 8400001

Bardstown, Kentucky, United States

Investigational Site Number 8400002

Salt Lake City, Utah, United States

Countries

United States

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

https://www.trialsummaries.com/Study/StudyDetails?id=25270&tenant=MT_SNY_9011

GRC00101 Plain Language Results Summary

Other Identifiers

U1111-1238-1821

Identifier Type: OTHER

Identifier Source: secondary_id

GRC00101

Identifier Type: -

Identifier Source: org_study_id